Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura
Archivio

Background and objectives: In economic evaluations in oncology, adjusted survival should be generated if imbalances in prognostic/predictive factors across treatment arms are present. To date, no formal guidance has been developed regarding how such adjustments should be made. We compared various covariate-adjusted survival modeling approaches, as applied to the ENDEAVOR

PharmacoEconomics 2019; 37 (5): 727–737. /  Majer IM, Castaigne JG, Palmer S, et al.

Lessons learned: The combination of ofatumumab and bendamustine in elderly patients with diffuse large B-cell lymphoma demonstrated modest efficacy compared with standard of care.The poor response may have been due to patient age and the high rate of treatment discontinuation. Background: This phase II trial evaluated the efficacy of bendamustine and ofatumumab in elderly patients

Oncologist 2019 May 9 [Epub ahead of print] /  Flinn IW, Erter J, Daniel Dlinn IW,  et al.

Background: With the ever-increasing complexity of cancer treatments, oncology medication patient education is becoming a progressively important component of cancer care. Despite this, cancer patients frequently report that they receive inadequate information and feel that their education needs have not been met. Objective: To explore patients' perspectives of optimal oncology medication

J Oncol Pharm Pract 2019 Apr 18 [Epub ahead of print] /  Kaupp K, Scott S, Minard L, et al.

Background: Patients with advanced cancer commonly experience pain and it is least controlled in community settings. Community pharmacists in the UK already offer medicines optimisation consultations although not for this patient group. Objective: To determine whether medicines consultations for patients with advanced cancer pain are feasible and acceptable. SettingCommunity-dwelling patients with advanced

Int J Clin Pharm 2019 Apr. [Epub ahead of print] /  Edwards Z, Bennett MI, Blenkinsopp A.

This paper provides an educational review covering the consideration of costs for cost-effectiveness analysis (CEA), summarising relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit costs to healthcare resource-use data for patients. Trial-based evaluations and decision analytic modelling represent the two main vehicles

PharmacoEconomics 2019; 37(5):631–643. /   Franklin M, Lomas J, Walker S, et al.

Background: The majority of patients with chronic lymphocytic leukemia (CLL) are older and have multiple comorbidities, including other cancer diagnoses. These patients are routinely excluded from participation in clinical trials. Objective: In this phase II study, we determined the activity and toxicity of ofatumumab, a fully human anti-CD20 monoclonal antibody, in older

J Geriatr Oncol  2019 Apr 17. [Epub ahead of print] /  Vitale C, Falchi L, Ciccone M et al.

Objectives: To identify perceptions of decision-makers and staff at a local hospital about the pharmacist's role in transitions of care (TOC) programs. Setting: Independent community pharmacy located inside a local community hospital. Practise description: Pharmacy personnel offer a bedside delivery service to hospital patients and have professional relationships with administration Practise innovation: Pharmacy

J Am Pharm Assoc 2019 May 9 [Epub ahead of print] /  Foster AR, Gatewood SS, Kaefer TN, et al.

Purpose: Cancer chemotherapy is a high-risk process. To improve patient safety, a systematic pharmaceutical analysis of chemotherapy prescriptions is performed in our institution. The aim of this study was to assess the impact of pharmaceutical interventions (PIs) on the safety of patient chemotherapy prescriptions. Methods: This prospective cross-sectional study was conducted

J Oncol Pharm Pract 2019;25(5):1195-1203. /  Daupin J, Perrin G, Lhermitte-Pastor C, et al.

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution. The progresses made in understanding its biology led to the development of targeted therapies. In this review, we summarize the current and future approaches in management of adult ALL. Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 tyrosine kinase, monoclonal antibodies

Leuk Lymphoma 2019 May 16:1-16. [Epub ahead of print] /  Rafei H, Kantarjian HM, Jabbour EJ, et al.

Background: Discharge medication reconciliation (Discharge MedRec) was implemented on one unit at a large urban teaching hospital, and was to be expanded across the rest of the hospital and the health authority's various sites by the end of 2018. Clinical pharmacists on the Acute Care for the Elderly unit carried

Can J Hosp Pharm 2019;72(2):111-118. /  Lee R, Malfair S, Schneider J, et al.